Unknown

Dataset Information

0

Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.


ABSTRACT: Treatment patterns and outcomes are unclear for metastatic breast cancer (MBC) patients diagnosed with hormone receptor-positive (HR+), human epidermal growth factor 2-positive (HER2+) disease. This study aimed to: (1) examine the utilization of first-line therapy among HR+/HER2+/MBC patients and (2) compare overall survival (OS) between the identified regimens. We analyzed National Cancer Database patients (HR+/HER2+/MBC) who were treated between 2010 and 2015. Multivariable logistic and Cox regression were used to: (1) identify independent predictors of treatment receipt and (2) determine significant prognostic factors for OS. Kaplan-Meier method and log-rank test were used to estimate and evaluate OS, respectively. Propensity scores were added to all multivariate OS models, thereby accounting for bias in treatment receipt. Of 6,234 patients analyzed, 3770 (60.5%) received hormonal therapy and 2464 (39.5%) received chemotherapy. Receipt of hormonal therapy was associated with older age, grade 1/grade 2 disease, no visceral involvement, higher comorbidity scores, and being white. Multivariate analysis suggest patients receiving hormonal therapy?+?anti-HER2 experienced improved OS, when compared to chemotherapy?+?anti-HER2 (HR: 0.74, p?=?0.004). Overall, the cohort receiving hormonal therapy?+?anti-HER2 reported the highest 5-year OS (hormonal?+?anti-HER2: 47.5% vs. chemotherapy?+?anti-HER2: 39.8% vs. hormonal: 38.5% vs. chemotherapy: 36.3%, p?

SUBMITTER: Statler AB 

PROVIDER: S-EPMC6889133 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.

Statler Abby B AB   Hobbs Brian P BP   Wei Wei W   Gupta Annie A   Blake Cassann N CN   Nahleh Zeina A ZA  

Scientific reports 20191202 1


Treatment patterns and outcomes are unclear for metastatic breast cancer (MBC) patients diagnosed with hormone receptor-positive (HR+), human epidermal growth factor 2-positive (HER2+) disease. This study aimed to: (1) examine the utilization of first-line therapy among HR+/HER2+/MBC patients and (2) compare overall survival (OS) between the identified regimens. We analyzed National Cancer Database patients (HR+/HER2+/MBC) who were treated between 2010 and 2015. Multivariable logistic and Cox re  ...[more]

Similar Datasets

| S-EPMC10284953 | biostudies-literature
| S-EPMC9355808 | biostudies-literature
| S-EPMC9553912 | biostudies-literature
| S-EPMC7027476 | biostudies-literature
| S-EPMC10578436 | biostudies-literature
| S-EPMC7568708 | biostudies-literature
| S-EPMC9803673 | biostudies-literature
| S-EPMC8053791 | biostudies-literature
| S-EPMC11365913 | biostudies-literature
| S-EPMC8741603 | biostudies-literature